NCT06058442
The Pancreatic Enzymes After Gastrectomy Trial
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 8 versions: 8 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 21 words
- Trial sites expanded: 12 → 15 locations
- Secondary endpoints: details revised at 1 of 13 entries
- Notable Primary and study completion pushed from Jun 2027 to Feb 2028
- Eligibility criteria expanded, about 1 word
- Trial sites expanded: 9 → 12 locations
- Notable Primary and study completion dates: Apr 2026 to Jun 2027
- Eligibility criteria expanded, about 11 words
- Study sites: 7 to 9
- Minor Study sites: 6 to 7v5
- Minor Study sites: 4 to 6v4
Show 2 earlier versionsHide 2 earlier versions
- Minor Secondary endpoints: details revised at 11 of 13 entriesv3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 1 to 4
- Start date changed from estimate of Oct 2023 to Jan 24, 2024
- Secondary endpoints revised (13)
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Disease specific quality of life (QOL)
Timeframe: 6 months
Secondary (13)
Nutritional supplementation or weight loss
Weight
Serum haemoglobin
Total protein
Albumin
Show 8 moreShow less
Glucose
HbA1c
Cholesterol
Vitamin A
Vitamin B12
Vitamin D
Vitamin E
Vitamin K
Arms and interventions
NORTASE®Experimental
PlaceboPlacebo comparator
Drugs: NORTASE®, Placebo
Sites
15 sites in 1 country